Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patients
- 30 June 1995
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 17 (3), 425-432
- https://doi.org/10.1016/0149-2918(95)80107-3
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pharmacokinetic, Safety, and Antiviral Profiles of Oral Ganciclovir in Persons Infected with Human Immunodeficiency Virus: A Phase I/II StudyThe Journal of Infectious Diseases, 1995
- GanciclovirDrugs, 1990
- Use of Ganciclovir to Treat Serious Cytomegalovirus Infections in Patients with AIDSThe Journal of Infectious Diseases, 1987
- Treatment of Serious Cytomegalovirus Infections with 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine in Patients with AIDS and Other ImmunodeficienciesNew England Journal of Medicine, 1986
- Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine on Serious Cytomegalovirus Disease in Eight Immunosuppressed Homosexual MenAnnals of Internal Medicine, 1986
- Sensitivity of Clinical Isolates of Human Cytomegalovirus to 9-(1,3-Dihydroxy-2-Prop.oxymethyl)GuanineThe Journal of Infectious Diseases, 1985